局部治疗在直肠癌盆腔侧方淋巴结转移中的作用

doi:10.3760/cma.j.cn113030-20200415-00182

Abstract
Figure/Table
References(50)
Related Citation (11)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Lateral pelvic lymph node (LPLN) metastasis is a poor prognostic factor for rectal cancer, which is more common in low site, T3-T4 stage, and positive lymph nodes in mesorectum. However, there is no accurate predictor of metastasis. At present, high-resolution MRI is the optimal diagnosis of LPLN metastasis, but the threshold value is still unclear. The treatment mode of LPLN metastasis in locally advanced rectal cancer is controversial worldwide. European and American countries advocate chemoradiotherapy combined with total mesorectal resection, while Japan recommends total mesorectal resection combined with LPLN dissection. The combination of radiotherapy and surgery could achieve good local control. Further more, by using the information of lateral lymph nodes before and after radiotherapy, patients with high risk can be screened for intensive treatment, such as LPLN dissection or dose-escalation approaches. Currently, there is still a lack of high-quality evidence on the efficacy of various approaches in the treatment of LPLN metastasis, and more research is needed to improve the treatment strategies.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Tang Yuan
	Jin Jing

Key words： Rectal neoplasm, lateral pelvic lymph node metastasis/surgery Rectal neoplasm, lateral pelvic lymph node metastasis/radiotherapy Rectal neoplasm, lateral pelvic lymph node metastasis/combined treatment

Received: 15 April 2020

Corresponding Authors: Jin Jing, Email:jinjing@csco.org.cn

Cite this article:

Tang Yuan,Jin Jing. Effect of local treatment on lateral pelvic lymph node metastasis in rectal cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(1): 97-101.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20200415-00182 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2022/V31/I1/97

[1] FUJITA S, YAMAMOTO S, AKASU T, et al. Lateral pelvic lymph node dissection for advanced lower rectal cancer[J]. Br J Surg, 2003, 90(12):1580-1585. DOI:10.1002/bjs.4350.
[2] QUADROS CA, FALCÃO MF, CARVALHO ME, et al. Metastases to retroperitoneal or lateral pelvic lymph nodes indicated unfavorable survival and high pelvic recurrence rates in a cohort of 102 patients with low rectal adenocarcinoma[J]. J Surg Oncol, 2012, 106(6):653-658. DOI:10.1002/jso.23144.
[3] AKIYOSHI T, WATANABE T, MIYATA S, et al. Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer:is it regional or distant disease?[J]. Ann Surg, 2012, 255(6):1129-1134. DOI:10.1097/SLA.0b013e3182565d9d.
[4] KUSTERS M, BOSMAN SJ, VAN ZOGGEL DM, et al. Local recurrence in the lateral lymph node compartment:improved outcomes with induction chemotherapy combined with multimodality treatment[J]. Ann Surg Oncol, 2016, 23(6):1883-1889. DOI:10.1245/s10434-016-5098-2.
[5] YAGI R, SHIMADA Y, KAMEYAMA H, et al. Clinical significance of extramural tumor deposits in the lateral pelvic lymph node area in low rectal cancer:a retrospective study at two institutions[J]. Ann Surg Oncol, 2016, 23(Suppl 4):552-558. DOI:10.1245/s10434-016-5379-9.
[6] CANESSA CE, MIEGGE LM, BADO J, et al. Anatomic study of lateral pelvic lymph nodes:implications in the treatment of rectal cancer[J]. Dis Colon Rectum, 2004, 47(3):297-303. DOI:10.1007/s10350-003-0052-3.
[7] WATANABE T, MURO K, AJIOKA Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer[J]. Int J Clin Oncol, 2018, 23(1):1-34. DOI:10.1007/s10147-017-1101-6.
[8] GLYNNE-JONES R, WYRWICZ L, TIRET E, et al. Rectal cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4):iv22-iv40. DOI:10.1093/annonc/mdx224.
[9] SUGIHARA K, KOBAYASHI H, KATO T, et al. Indication and benefit of pelvic sidewall dissection for rectal cancer[J]. Dis Colon Rectum, 2006, 49(11):1663-1672. DOI:10.1007/s10350-006-0714-z.
[10] TAN KY, YAMAMOTO S, FUJITA S, et al. Improving prediction of lateral node spread in low rectal cancers—multivariate analysis of clinicopathological factors in 1, 046 cases[J]. Langenbecks Arch Surg, 2010, 395(5):545-549. DOI:10.1007/s00423-010-0642-1.
[11] UENO M, OYA M, AZEKURA K, et al. Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer[J]. Br J Surg, 2005, 92(6):756-763. DOI:10.1002/bjs.4975.
[12] FUJITA S, YAMAMOTO S, AKASU T, et al. Prognostic factors of rectal cancer patients with lateral pelvic lymph node metastasis[J]. Hepatogastroenterology, 2012, 59(120):2494-2497. DOI:10.5754/hge12153.
[13] FUJITA S, MIZUSAWA J, KANEMITSU Y, et al. Mesorectal excision with or without lateral lymph node dissection for clinical stage Ⅱ/Ⅲ lower rectal cancer (JCOG0212):a multicenter, randomized controlled, noninferiority trial[J]. Ann Surg, 2017, 266(2):201-207. DOI:10.1097/SLA.0000000000002212.
[14] UENO H, MOCHIZUKI H, HASHIGUCHI Y, et al. Potential prognostic benefit of lateral pelvic node dissection for rectal cancer located below the peritoneal reflection[J]. Ann Surg, 2007, 245(1):80-87. DOI:10.1097/01.sla.0000225359.72553.8c.
[15] ISHIBE A, OTA M, WATANABE J, et al. Prediction of lateral pelvic lymph-node metastasis in low rectal cancer by magnetic resonance imaging[J]. World J Surg, 2016, 40(4):995-1001. DOI:10.1007/s00268-015-3299-7.
[16] KIM NK, KIM MJ, PARK JK, et al. Preoperative staging of rectal cancer with MRI:accuracy and clinical usefulness[J]. Ann Surg Oncol, 2000, 7(10):732-737. DOI:10.1007/s10434-000-0732-3.
[17] YAMAOKA Y, KINUGASA Y, SHIOMI A, et al. Preoperative chemoradiotherapy changes the size criterion for predicting lateral lymph node metastasis in lower rectal cancer[J]. Int J Colorectal Dis, 2017, 32(11):1631-1637. DOI:10.1007/s00384-017-2873-x.
[18] OGAWA S, HIDA J, IKE H, et al. Selection of lymph node-positive cases based on perirectal and lateral pelvic lymph nodes using magnetic resonance imaging:study of the japanese society for cancer of the colon and rectum[J]. Ann Surg Oncol, 2016, 23(4):1187-1194. DOI:10.1245/s10434-015-5021-2.
[19] AKASU T, ⅡNUMA G, TAKAWA M, et al. Accuracy of high-resolution magnetic resonance imaging in preoperative staging of rectal cancer[J]. Ann Surg Oncol, 2009, 16(10):2787-2794. DOI:10.1245/s10434-009-0613-3.
[20] OGAWA S, ITABASHI M, HIROSAWA T, et al. Lateral pelvic lymph node dissection can be omitted in lower rectal cancer in which the longest lateral pelvic and perirectal lymph node is less than 5 mm on MRI[J]. J Surg Oncol, 2014, 109(3):227-233. DOI:10.1002/jso.23478.
[21] KOBAYASHI H, KIKUCHI A, OKAZAKI S, et al. Diagnostic performance of multidetector row computed tomography for assessment of lymph node metastasis in patients with distal rectal cancer[J]. Ann Surg Oncol, 2015, 22(1):203-208. DOI:10.1245/s10434-014-3972-3.
[22] ISHIHARA S, KAWAI K, TANAKA T, et al. Diagnostic value of FDG-PET/CT for lateral pelvic lymph node metastasis in rectal cancer treated with preoperative chemoradiotherapy[J]. Tech Coloproctol, 2018, 22(5):347-354. DOI:10.1007/s10151-018-1779-0.
[23] AMANO K, FUKUCHI M, KUMAMOTO K, et al. Pre-operative evaluation of lateral pelvic lymph node metastasis in lower rectal cancer:comparison of three different imaging modalities[J]. J Anus Rectum Colon, 2020, 4(1):34-40. DOI:10.23922/jarc.2019-022.
[24] OGAWA S, HIDA J, IKE H, et al. Selection of lymph node-positive cases based on perirectal and lateral pelvic lymph nodes using magnetic resonance imaging:study of the japanese society for cancer of the colon and rectum[J]. Ann Surg Oncol, 2016, 23(4):1187-1194. DOI:10.1245/s10434-015-5021-2.
[25] SYK E, TORKZAD MR, BLOMQVIST L, et al. Radiological findings do not support lateral residual tumour as a major cause of local recurrence of rectal cancer[J]. Br J Surg, 2006, 93(1):113-119. DOI:10.1002/bjs.5233.
[26] SUGIHARA K, KOBAYASHI H, KATO T, et al. Indication and benefit of pelvic sidewall dissection for rectal cancer[J]. Dis Colon Rectum, 2006, 49(11):1663-1672. DOI:10.1007/s10350-006-0714-z.
[27] UENO H, MOCHIZUKI H, HASHIGUCHI Y, et al. Potential prognostic benefit of lateral pelvic node dissection for rectal cancer located below the peritoneal reflection[J]. Ann Surg, 2007, 245(1):80-87. DOI:10.1097/01.sla.0000225359.72553.8c.
[28] KOBAYASHI H, MOCHIZUKI H, KATO T, et al. Outcomes of surgery alone for lower rectal cancer with and without pelvic sidewall dissection[J]. Dis Colon Rectum, 2009, 52(4):567-576. DOI:10.1007/DCR.0b013e3181a1d994.
[29] HOMMA Y, HAMANO T, OTSUKI Y, et al. Total number of lymph node metastases is a more significant risk factor for poor prognosis than positive lateral lymph node metastasis[J]. Surg Today, 2015, 45(2):168-174. DOI:10.1007/s00595-014-0913-5.
[30] WATANABE T, MURO K, AJIOKA Y, et al. Japanese Society for cancer of the colon and rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer[J]. Int J Clin Oncol, 2018, 23(1):1-34. DOI:10.1007/s10147-017-1101-6.
[31] MYERSON RJ, GAROFALO MC, EL NAQA I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer:a radiation therapy oncology group consensus panel contouring atlas[J]. Int J Radiat Oncol Biol Phys, 2009, 74(3):824-830. DOI:10.1016/j.ijrobp.2008.08.070
[32] 中国医师协会结直肠肿瘤专委会放疗专委会,中华医学会放射肿瘤治疗学分会,唐源,等. 直肠癌术前/术后适形/调强放疗靶区勾画共识与图谱[J]. 中华放射肿瘤学杂志,2018, 27(3):227-234. DOI:10.3760/cma.j.issn.1004-4221.2018.03.001.
Radiotherapy Special Committee of Colorectal Cancer Special Committee of Chinese Medical Doctor Association, Radiation Oncology Therapy Branch of Chinese Medical Association, TANG Y, et al. Consensus and atlas of preoperative/ postoperative conformal/IMRT targets for rectal cancer[J]. Chin J Radiat Oncol, 2018, 27(3):227-234. DOI:10.3760/cma.j.issn.1004-4221.2018.03.001.
[33] VAN GIJN W, MARIJNEN CA, NAGTEGAAL ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer:12-year follow-up of the multicentre, randomisedcontrolled TME trial[J]. Lancet Oncol, 2011, 12(6):575-582. DOI:10.1016/S1470-2045(11)70097-3.
[34] BOSSET J F, COLLETTE L, CALAIS G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer[J]. N Engl J Med, 2006, 355(11):1114-1123. DOI:10.1056/NEJMoa060829.
[35] ROH M S, COLANGELO LH, O′CONNELL MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum:NSABP R-03[J]. J Clin Oncol, 2009, 27(31):5124-5130. DOI:10.1200/JCO.2009.22.0467.
[36] SAUER R, LIERSCH T, MERKEL S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer:results of the German CAO/ARO/AIO-94 randomized phase Ⅲ trial after a median follow-up of 11 years[J]. J Clin Oncol, 2012, 30(16):1926-1933. DOI:10.1200/JCO.2011.40.1836.
[37] PARK JH, YOON SM, YU CS, et al. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer[J]. Cancer, 2011, 117(16):3703-3712. DOI:10.1002/cncr.25943.
[38] KUSTERS M, BEETS GL, VAN DE VELDE CJ, et al. A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence[J]. Ann Surg, 2009, 249(2):229-235. DOI:10.1097/SLA.0b013e318190a664.
[39] KUSTERS M, MARIJNEN CA, VAN DE VELDE CJ, et al. Patterns of local recurrence in rectal cancer;a study of the Dutch TME trial[J]. Eur J Surg Oncol, 2010, 36(5):470-476. DOI:10.1016/j.ejso.2009.11.011.
[40] KIM JC, TAKAHASHI K, YU CS, et al. Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer[J]. Ann Surg, 2007, 246(5):754-762. DOI:10.1097/SLA.0b013e318070d587.
[41] OH HK, KANG SB, LEE SM, et al. Neoadjuvant chemoradiotherapy affects the indications for lateral pelvic node dissection in mid/low rectal cancer with clinically suspected lateral node involvement:a multicenter retrospective cohort study[J]. Ann Surg Oncol, 2014, 21(7):2280-2287. DOI:10.1245/s10434-014-3559-z.
[42] KUSTERS M, SLATER A, MUIRHEAD R, et al. What to do with lateral nodal disease in low locally advanced rectal cancer? A call for further reflection and research[J]. Dis Colon Rectum, 2017, 60(6):577-585. DOI:10.1097/DCR.0000000000000834.
[43] OGURA A, KONISHI T, CUNNINGHAM C, et al. Neoadjuvant (chemo) radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes:results of the multicenter lateral node study of patients with low cT3/4 rectal cancer[J]. J Clin Oncol, 2019, 37(1):33-43. DOI:10.1200/JCO.18.00032.
[44] KIM MJ, KIM TH, KIM DY, et al. Can chemoradiation allow for omission of lateral pelvic node dissection for locally advanced rectal cancer?[J]. J Surg Oncol, 2015, 111(4):459-464. DOI:10.1002/jso.23852.
[45] OGURA A, KONISHI T, BEETS GL, et al. Lateral nodal features on restaging magnetic resonance imaging associated with lateral local recurrence in low rectal cancer after neoadjuvant chemoradiotherapy or radiotherapy[J]. JAMA Surg, 2019, 154(9):e192172. DOI:10.1001/jamasurg.2019.2172.
[46] 韦婷,冯成军,陈海辉. 术前侧方淋巴结推量照射对局部进展期直肠癌预后的影响[J]. 肿瘤研究与临床,2019, 31(2):113-117. DOI:10.3760/cma.j.issn.1006-9801.2019.02.009.
WEI T, FENG CJ, CHEN HH. Effect of preoperative lateral lymph node push volume irradiation on the prognosis of locally progressive rectal cancer[J]. Cancer Res Clin, 2019, 31(2):113-117. DOI:10.3760/cma.j.issn.1006-9801.2019.02.009.
[47] HARTVIGSON PE, APISARNTHANARAX S, SCHAUB S, et al. Radiation therapy dose escalation to clinically involved pelvic sidewall lymph nodes in locally advanced rectal cancer[J]. Adv Radiat Oncol, 2019, 4(3):478-486. DOI:10.1016/j.adro.2019.03.007.
[48] SAMMOUR T, CHANG GJ. Lateral pelvic lymph node dissection and radiation treatment for rectal cancer:mutually exclusive or mutually beneficial?[J]. Ann Gastroenterol Surg, 2018, 2(5):348-350. DOI:10.1002/ags3.12197.
[49] FOKAS E, ALLGAUER M, POLAT B, et al. Randomized phase Ⅱ trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer:CAO/ARO/AIO-12[J]. J Clin Oncol, 2019, 37(34):3212-3222. DOI:10.1200/JCO.19.00308.
[50] FERNÁNDEZ-MARTOS C, PERICAY C, LOSA F, et al. Effect of aflibercept plus modified FOLFOX6 induction chemotherapy before standard chemoradiotherapy and surgery in patients with high-risk rectal adenocarcinoma:the GEMCAD 1402 randomized clinical trial[J]. JAMA Oncol, 2019, 5(11):1566-1573. DOI:10.1001/jamaoncol.2019.2294.